BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22978340)

  • 1. Can targeted therapy be successful without metronomic scheduling?
    André N; Pasquier E; Kamen B
    Curr Top Med Chem; 2012; 12(15):1639-42. PubMed ID: 22978340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mathematical model to study low-dose metronomic scheduling for chemotherapy.
    Arora G; Bairagi N; Chatterjee S
    Math Biosci; 2024 Jun; 372():109186. PubMed ID: 38580078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
    Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management.
    Mahmud F; Chung SW; Alam F; Choi JU; Kim SW; Kim IS; Kim SY; Lee DS; Byun Y
    J Control Release; 2017 Mar; 249():42-52. PubMed ID: 28093298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer].
    Zhang S; Liu J; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):232-9. PubMed ID: 25936888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
    André N; Padovani L; Pasquier E
    Future Oncol; 2011 Mar; 7(3):385-94. PubMed ID: 21417902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?
    Ledzewicz U; Schättler H
    Cancer Lett; 2017 Aug; 401():74-80. PubMed ID: 28323033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
    Gnoni A; Silvestris N; Licchetta A; Santini D; Scartozzi M; Ria R; Pisconti S; Petrelli F; Vacca A; Lorusso V
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):46-61. PubMed ID: 25656744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field.
    Gaspar TB; Henriques J; Marconato L; Queiroga FL
    Vet Comp Oncol; 2018 Mar; 16(1):2-11. PubMed ID: 28317239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models.
    Terterov IN; Chubenko VA; Knyazev NA; Klimenko VV; Bogdanov AA; Moiseyenko VM; Bogdanov AA
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):867-878. PubMed ID: 34351468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic dosing of chemotherapy: applications in pediatric oncology.
    Stempak D; Seely D; Baruchel S
    Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.
    Lambrescu I; Fica S; Martins D; Spada F; Cella C; Bertani E; Rubino M; Gibelli B; Grana C; Bonomo G; Funicelli L; Ravizza D; Pisa E; Zerini D; Ungaro A; Fazio N;
    Cancer Treat Rev; 2017 Apr; 55():46-56. PubMed ID: 28314176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomics chemotherapy: time for computational decision support.
    Barbolosi D; Ciccolini J; Meille C; Elharrar X; Faivre C; Lacarelle B; André N; Barlesi F
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):647-52. PubMed ID: 25082520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.
    Loven D; Hasnis E; Bertolini F; Shaked Y
    Drug Discov Today; 2013 Feb; 18(3-4):193-201. PubMed ID: 22868084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor endothelial cells as a potential target of metronomic chemotherapy.
    Kim JY; Kim YM
    Arch Pharm Res; 2019 Jan; 42(1):1-13. PubMed ID: 30604201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic scheduling: the future of chemotherapy?
    Gasparini G
    Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.